EMQN Best Practice Guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies

This article has been amended since online publication. A corrigendum also appears in this issue.

Joanne Traeger-Synodinos*,1, Cornelis L Harteveld2, John M Old3, Mary Petrou4, Renzo Galanello5, Piero Giordano2, Michael Angastioniotis6, Barbara De la Salle7, Shirley Henderson3 and Alison May8 on behalf of contributors to the EMQN haemoglobinopathies best practice meeting

Haemoglobinopathies constitute the commonest recessive monogenic disorders worldwide, and the treatment of affected individuals presents a substantial global disease burden. Carrier identification and prenatal diagnosis represent valuable procedures that identify couples at risk for having affected children, so that they can be offered options to have healthy offspring. Molecular diagnosis facilitates prenatal diagnosis and definitive diagnosis of carriers and patients (especially ‘atypical’ cases who often have complex genotype interactions). However, the haemoglobin disorders are unique among all genetic diseases in that identification of carriers is preferable by haematological (biochemical) tests rather than DNA analysis. These Best Practice guidelines offer an overview of recommended strategies and methods for carrier identification and prenatal diagnosis of haemoglobinopathies, and emphasize the importance of appropriately applying and interpreting haematological tests in supporting the optimum application and evaluation of globin gene DNA analysis.

European Journal of Human Genetics (2015) 23, 426–437; doi:10.1038/ejhg.2014.131; published online 23 July 2014

INTRODUCTION

These Best Practice guidelines offer an overview of recommended strategies and methods for carrier identification and prenatal diagnosis of haemoglobinopathies. They are complementary to, and can be used in conjunction with, other guidelines, for example from the British Society for Haematology,1 the ENERCA recommendations for preconception or antenatal screening,2 prenatal diagnosis and genetic counselling of haemoglobinopathies3 and the UK NHS Sickle Cell and Thalassaemia screening programme.4 They cover not only DNA analysis but include also details of haematological (biochemical) tests. This is to emphasize the importance of appropriately applying and interpreting haematological tests in supporting the optimum application and evaluation of globin gene DNA analysis. Most of the methods recommended in these guidelines, especially for haematology, have been in use for several years, and few technical advances have been translated into clinical practice.4 Due to worldwide population migrations, carrier identification and prenatal diagnosis of the haemoglobinopathies is currently appropriate in most countries, even the traditionally non-endemic countries of Northern and Western Europe. Thus these guidelines are expected to be useful for laboratories in all regions of the world, and not only those where the haemoglobinopathies are traditionally endemic.

External Quality Assessment (EQA) is an intrinsic part of Best Practice. EQA provides a long-term, retrospective assessment of laboratory performance. Participation in EQA (when available) is encouraged and essential, for any laboratory already accredited or seeking accreditation to international standards, for example ISO 17025, ISO 15189 or equivalent.5,6 Unless dictated by legislation, choice of EQA provider lies with the laboratory, but use of an accredited EQA programme (to ISO 17043) is recommended, wherever possible.

 Throughout the guidelines, for reasons of space, some globin gene variants have been referred to using ‘traditional’ names rather than nomenclature recommended by the Human Genome Variation Society (HGVS). Relevant HGVS nomenclature can be found in the supporting information (Supplementary Table 1) and the HbVar database: http://globin.bx.psu.edu/hbvar/menu.html.

Description of the disease group

Haemoglobinopathies constitute the commonest recessive monogenic disorders worldwide.7,8 They are caused by variants that affect the genes that direct synthesis of the globin chains of haemoglobin, and may result in altered synthesis (thalassaemia syndromes and hereditary persistence of fetal haemoglobin (HPFH)) or structural
changes (sickling of the red blood cells, haemolytic anaemia, polycythaemia or more rarely cyanosis).

Thalassaemia variants and various abnormal haemoglobins interact to produce a wide range of disorders of varying degrees of severity. There are four main categories of severe disease states, for which genetic counselling, and possibly prenatal diagnosis, is indicated, as follows (Tables 1, 2 and 3).9

- Thalassaemia major (co-inheritance of two α-thalassaemia variants including inheritance of δβ-thalassaemia variants and Hb Lepore).
- Sickle cell syndromes (for example Hb S/Hb S, Hb S/Hb C, Hb S/Hbthalassaemia, Hb S/Hb D-Punjab, Hb S/Hb O-Arab, Hb S/Hb Lepore, Hb S/Hb E).
- Hb Bart's Hydrops Fetalis syndrome (co-inheritance of α-thalassaemia variants with Hb E).
- Hb E thalassaemia (co-inheritance of β-thalassaemia variants with Hb E).
- Hb H thalassaemia (β-thalassaemia variants (silent), and (rarely) Hb H Hydrops Fetalis syndrome (genotype −/+).

In many populations β-thalassaemia syndromes (and related conditions caused by haemoglobin variants such as Hb S and Hb E) are clinically more relevant than the α-thalassaemias, since the severe forms are more common and require life-long treatment and clinical management. However, populations that have a high prevalence of α-thalassaemia defects, such as the Chinese and many South East Asian populations, or in countries with significant immigrant populations from these areas, α-thalassaemias are also relevant. The severest form of α-thalassaemia, Hb Bart's Hydrops Fetalis, is usually fatal as infants either die in utero (23–38 weeks) or shortly after birth (unless subjected to intrauterine blood transfusion therapy). Even with perinatal treatment it is a very severe condition with these patients requiring lifetime transfusion therapy and iron chelation and some children also have long term neurological complications.10 Furthermore, hydropic pregnancies are frequently associated with serious complications in the mother, and most pregnancies in which the fetus is diagnosed as affected are terminated due to the increased risk of both fetal and maternal morbidity.

### The genes and disease-causing variants

The major haemoglobin in adult life is Hb A, a tetramer composed of two alpha and two beta globin chain subunits (α₂β₂). Each subunit consists of a globin chain wrapped around a haem group containing iron to which O₂ can bind. The single gene encoding β-globin chains is located on the short arm of chromosome 11 (11p15.5), within the so-called β-globin gene cluster, and the two genes encoding the α-globin chains are located on the short arm of chromosome 16 (16p13.3), within the α-globin gene cluster.

In the HBB gene locus, there are over 280 genetic variants (variants) causing β-thalassaemia have been described, the majority of which are point variants. In the HBA1 and HBA2 genes and wider loci, more than 100 α-thalassaemia variants have been reported most of which involve deletions within the α-globin gene cluster.11 In addition, more than 1150 DNA variants causing structural protein variants have been identified.

| Genotype interaction | Disorder expected | Appropriate to offer PND |
|----------------------|-------------------|-------------------------|
| Homozygous           |                   |                         |
| β- or severe β⁺-thalassaemia | Thalassaemia major | Yes                     |
| Mild β-thalassaemia  | Thalassaemia intermedia | Occasionally⁴ |
| Mild β⁺⁺-thalassaemia (silent) | Very mild thalassaemia intermedia | No |
| δβ-thalassaemia      | Thalassaemia intermedia | Occasionally⁴ |
| Hb Lepore            | Thalassaemia intermedia to major (variable) | Occasionally⁴ |
| HPFH                 | Not clinically relevant | No                      |
| Hb C                 | Not clinically relevant | No                      |
| Hb D-Punjab          | Not clinically relevant | No                      |
| Hb E                 | Not clinically relevant | No                      |
| Hb D-Arab            | Not clinically relevant | No                      |
| Compound heterozygous|                   |                         |
| β⁺/β⁺⁺-thalassaemia  | Thalassaemia major | Yes                     |
| Mild β⁺⁺/β⁺⁺-thalassaemia | Thalassaemia intermedia to major (variable) | Occasionally⁴ |
| δβ⁺⁺/β⁺⁺-thalassaemia | Thalassaemia intermedia to major (variable) | Occasionally⁴ |
| δβ⁺⁺/mild β⁺⁺-thalassaemia | Mild thalassaemia intermedia | Occasionally⁴ |
| δβ⁺⁺/Hb Lepore       | Thalassaemia intermedia | Occasionally⁴ |
| Hb Lepore/β⁺⁺-thalassaemia | Thalassaemia major | Yes                     |
| Hb C/β⁺⁺ or severe β⁺⁺-thalassaemia | β-thalassaemia trait to intermedia (variable) | Occasionally⁴ |
| Hb C/mild β⁺⁺-thalassaemia | Not clinically relevant | No                      |
| Hb D-Punjab/β⁺⁺-thalassaemia | Not clinically relevant | No                      |
| Hb E/β⁺⁺ or severe β⁺⁺-thalassaemia | Thalassaemia intermedia to major (variable) | Yes                     |
| Hb D-Arab/β⁺⁺-thalassaemia | Severe thalassaemia intermedia | Yes                     |
| αααα⁺⁺-thalassaemia   | Mild thalassaemia intermedia | No                      |
| αααα⁺⁺⁺⁺-thalassaemia  | Mild to severe thalassaemia intermedia (variable) | Occasionally⁴ |

Note: The decision to have prenatal diagnosis belongs to the couple, once they have had comprehensive counselling.

⁴Couples with genotypes that may lead to offspring with unpredictable phenotypes occasionally select to have prenatal diagnosis or PGD.
to avoid the birth of an affected child by opting for gamete donation or adoption. However, offered the reproductive choice to avoid the birth of affected children, or when the haematological/biochemical results are unclear. Depending on acceptable practices in each society, at-risk couples can then be helped to prepare for the possible birth of a severely affected child. Thus genetic services for haemoglobinopathies require close collaboration between several specialities, most notably haematology, genetic counselling, molecular genetics and fetal medicine.

These guidelines will focus on best practice in laboratory methods and interpretation of results for carrier identification and prenatal diagnosis. For the best strategy to detect at-risk couples there are certain factors that should also be taken into consideration, including the frequency of the disease in endemic and non-endemic immigration countries, the heterogeneity of the genetic defects in the target society, the knowledge of genotype-phenotype correlation (supported by access to original papers as well as to genomic databases), the resources available and finally the social, legal, cultural and religious factors.

In addition screening may target newborns or adolescents, or premarital, preconceptional or antenatal stages. For families wishing to avoid the birth of affected children, preconception or antenatal screening is the most effective approach and is widely applied in many high-risk populations. Newborn screening is less effective for primary screening and prospectively informing carriers about their risks of having affected children.

Table 2 Sickle cell disorders—interactions and indications for prenatal diagnosis and preimplantation genetic diagnosis (PGD)

| Genotype interaction | Disorder expected | Appropriate to offer PND |
|----------------------|-------------------|-------------------------|
| **Homozygous**       |                   |                         |
| Hb S                 | Sickle cell disease | Yes                     |
| **Compound heterozygous** |                   |                         |
| Hb S/β or severe β⁺-thalassaemia | Sickle cell disease | Yes                     |
| Hb S/mild β⁺-thalassaemia | Mild sickle cell disease | Occasionally⁴ |
| Hb S/β⁺-thalassaemia | Mild sickle cell disease | Occasionally⁴ |
| Hb S/Hb Lepore | Mild sickle cell disease | Occasionally⁴ |
| Hb S/HbC | Sickle cell disease (variable severity) | Yes                     |
| Hb S/Hb D-Punjab | Sickle cell disease | Yes                     |
| Hb S/Hb G-Arab | Sickle cell disease | Yes                     |
| Hb S/Hbs C-Harlem, S-Southend, S-Antilles | Sickle cell disease | Yes                     |
| Hb C/Hb S-Antilles | Sickle cell disease | Yes                     |
| Hb S/Hbs Quebec-Chori, C-Ndjamen, O-Tibesi | Sickle cell disease | Yes                     |
| Hb S/Hbs I-Toulouse, Shelby, Hope, North Shore | Haemolytic anaemia | No                     |
| Hb S/Hb E | Mild to severe sickle cell disease | Occasionally⁴ |
| Hb S/HPFH | Very mild sickle cell disease | No                     |

Note: The decision to have prenatal diagnosis belongs to the couple, once they have had comprehensive counselling.

*Combinations that may lead to offspring with unpredictable phenotypes occasionally select to have prenatal diagnosis or PGD.*

| Genotype interaction | Disorder expected | Appropriate to offer PND |
|----------------------|-------------------|-------------------------|
| **α-Thalassaemias—interactions and indications for prenatal diagnosis and preimplantation genetic diagnosis** |
| α⁺-thalassaemia (-/-) | Hb Bart’s hydrops fetalis | Yes                     |
| α⁺-thalassaemia (+/−α) | Not clinically relevant | No                     |
| α⁺-thalassaemia (α⁺/α⁺) | Severe α-thalassaemia carrier to severe Hb H disease | Occasionally⁴ |

Note: The decision to have prenatal diagnosis belongs to the couple, once they have had comprehensive counselling.

*Combinations that may lead to offspring with unpredictable phenotypes occasionally select to have prenatal diagnosis or PGD. Reported examples of potentially severe phenotypes include genotype combinations involving variants in the polyadenylation signal in the HBA2 gene, Hb Adana, Hb Agino, Hb Constant Spring and Hb Taybee (see Supplementary Table S1 for HbVar nomenclature).*

with an altered rate of synthesis. (Summarized in the HbVar database: http://globin.bx.psu.edu/hbvar/menu.html).

**Approaches for carrier detection**

Within the context of managing the health burden of the haemoglobinopathies, laboratory diagnosis plays a key role, identifying carrier couples and offering them reproductive choices. Haemoglobinopathies are unique among all genetic diseases in that detection of carriers is possible by haematological and biochemical tests rather than DNA analysis. Thus, it is recommended that, with currently available technologies, carrier detection should be mandatory using haematological and biochemical tests. However, DNA analysis should be employed for the determination of carrier status in complex cases or when the haematological/biochemical results are unclear. Depending on acceptable practices in each society, at-risk couples can then be offered the reproductive choice to avoid the birth-affected children, or helped to prepare for the possible birth of a severely affected child. Among the available options to avoid having affected children are, before marriage, a change in partner choice; or, after marriage, by remaining childless, opting for gamete donation or adoption. However, couples rarely take these options. Instead it is more common for at-risk couples to avoid the birth of an affected child by opting for pregnancy by choosing preimplantation genetic diagnosis (PGD). Both conventional prenatal diagnosis and PGD involve prior variant characterization in the parents and subsequent fetal (or embryo) DNA analysis. Thus genetic services for haemoglobinopathies require close collaboration between several specialities, most notably haematology, genetic counselling, molecular genetics and fetal medicine.

The decision to have prenatal diagnosis belongs to the couple, once they have had comprehensive counselling.

*Combinations that may lead to offspring with unpredictable phenotypes occasionally select to have prenatal diagnosis or PGD.*
reproductive risks, but it is applied in certain countries to support better infant healthcare through prompt identification of affected babies. Pre-operative screening of individuals from populations with increased incidence of sickle cell is also indicated.

HAEMATOLOGICAL METHODS FOR CARRIER DETECTION

‘Screening’ is distinct from ‘definitive’ diagnosis in that the purpose of screening is to test for a defined set of conditions using simple haematological/biochemical tests. Screening programme strategies use first- and second-line methods in order to obtain a reliable diagnosis, albeit essentially a presumptive diagnosis. If an unequivocal, definitive diagnosis is required, characterization methods based on either protein or DNA analysis must be used.

With the thalassaemias, screening will detect most cases of raised Hb A2 β-thalassaemia trait. However, there are often samples that present with haematology that is not consistent with typical β-thalassaemia trait (Tables 4 and 5) and, furthermore, there is no specific screening test of high-enough sensitivity for the clear identification of heterozygous α-thalassaemia, which is usually indicated once other states have been excluded. Definitive diagnosis of atypical cases and α-thalassaemia can only be made by DNA analysis.

When an abnormal haemoglobin is identified by screening methodology, the results obtained constitute a presumptive identification of the variant haemoglobin. It is important to remember that with phenotypic screening it is possible that some rarer conditions will not be detected and this has to be taken into account in the interpretation and reporting of results. For all samples, screening using haematological methods\cite{14} precedes genetic diagnosis.\cite{15}

Good laboratory practice also includes the minimization of clerical errors, particularly a danger in haematology laboratories undertaking carrier screening on large numbers of samples, sometimes numbering more than 1000 blood counts each day. Careful sample identification is essential (including: Full Name, Date of Birth, Sample date, if transfused in last 4 months). Bar coding is recommended for sample tracking. If acceptable and permitted, it is useful to note the ethnic origin, since many haemoglobin disorders are population-specific.\cite{7,11–13} Laboratory error rates for the methods utilized (if known), or a link to their availability, should be stated on reports.

Table 4 Interpretations to consider when the haematology is not consistent with typical β-thalassaemia trait

| Haematological parameters | Possible interpretation |
|---------------------------|-------------------------|
| Reduced red cell indices (MCV < 97 fl, MCH < 27 pg), normal Hb electrophoresis/HPLC/CE, normal %Hb A2 & %Hb F) | (i) Iron deficiency |
| Normal/borderline reduced red cell indices with raised Hb A2 | (ii) heterozygous α-thalassaemia |
| Normal or reduced red cell indices with raised Hb F (>5%) and normal or low Hb A2 | (iii) heterozygosity for mild β-thalassaemia variants (sometimes Hb A2 is borderline raised) |
| Normal red cell indices with normal/borderline Hb A2 | (iv) co-inheritance of heterozygous δ- with β-thalassaemia |
| Severely reduced red cell indices and raised Hb A2 | (v) heterozygous ζβ-thalassaemia |

Interaction of α- with β-thalassaemia

Carriers of β-thalassaemia with folic acid or vitamin B12 deficiency or hepatitis

Heterozygous ζβ-thalassaemia, ζβ-thalassaemia or HPFH

Triplication of α-genes (when implicated in family studies), KLF1 variants or mild β-thalassaemia variant

Multiple α-globin genes (> 4) and heterozygous β-thalassaemia

Note 1: Some Hb variants are not detected by electrophoretic or chromatographic procedures, but may be suspected due to the presence of abnormal haematological parameters and/or clinical symptoms. In such cases it is recommended that samples are analysed using mass spectrometry or DNA methods. Occasionally hyperunstable variants are present and these may only be found by DNA methodology as the protein produced is so unstable.

Note 2: When evaluating cases be aware of potential complex genotype interactions.

Table 5 Genetic variations associated with normal/borderline Hb A2 levels—a guideline of related haematological and biosynthetic characteristics

| Variation HGVS nomenclature NM_000518.4 (HBB) | Variation traditional nomenclature | MCV fl | MCH pg | Hb A2 | αβ ratio |
|-----------------------------------------------|-----------------------------------|--------|--------|--------|--------|
| c.−151C>T                                     | β −101 (C→T)                      | 88.5±7.8 | 30.1±1.0 | 3.1±1.0 | 1.3±0.4 |
| c.−142C>T                                     | β −92 (C/T)                       | 83.0±6.0 | 28.3±2.0 | 3.5±0.4 | 1.3±0.8 |
| c.−18C>G                                      | β +33 (C/G)                       | 82.0±9.2 | 27.1±3.4 | 2.5±1.4 | 1.3±0.6 |
| c.316-7C>G                                    | βIVS2-844 (C→G)                   | 96.0±4.0 | 30.3±1.8 | 3.2±0.2 | 1.0±0.6 |
| c.*6C>G                                       | β +1480 (C→G)                     | 88.3±9.5 | 27.9±6.0 | 2.7±0.8 | 1.6±0.4 |
|                                               | αα/αβ                            | 85.5±7.8 | 30.4±5.0 | 2.8±0.6 | 1.2±0.4 |
|                                               | KLF1 variants (29)                | 82.7±5.7 | 27.8±2.2 | 3.6±0.2 |
| c.−50A>C                                      | Cap +1 (A/C)                      | 23–26*   | 75–80*  | 3.4–3.8* | —      |
| c.92+6T>C                                     | βIVS1-6 (T→C)                     | 71.0±4.0 | 23.1±2.2 | 3.4±0.2 | 1.9±1.0 |
|                                               | δ + δ-thalassaemia                | 64.3±4.0 | 20.9±1.4 | 3.6±0.2 | 1.7±0.6 |

Values (mean±2SD or range (*)) are a guideline and represent those reported in various studies on carriers of these variants (prepared by R Galanello).

Note: It is recommended that subjects with borderline Hb A2 levels, particularly if their partner is a typical β-thalassaemia carrier, should be extensively investigated (α and β gene analysis, globin biosynthesis), although the majority usually have normal HBB and HBA genes. Borderline-raised Hb A2 levels in normal individuals are usually explained as the extreme distribution of the normal range of the Hb A2.

Furthermore, in couples where one partner is heterozygous for a severe α-thalassaemia defect and the other is a β-thalassaemia carrier, it is recommended that the HBA gene cluster be fully characterized in the β-thalassaemia carrier in order to preclude any risk of offspring with severe Hb H disease or Hb Bart’s hydrops.
It is strongly recommended that all haematological parameters be co-evaluated to avoid spurious conclusions. In addition, the extent to which the genetic test results explain the haematology results should be evaluated and stated.

FIRST-LINE HAEMATOLOGY METHODS
All haematological testing should be carried out on blood samples that are as fresh as possible. The complete blood count (CBC) or full blood count (FBC), haemoglobin pattern analysis and haemoglobin component quantification requires whole blood drawn into anticoagulant (EDTA). If necessary, blood can be transported and stored at 4°C.

Complete blood count
Electronic measurement is recommended, especially for MCV (mean cell volume), for which the measurements should be direct. All red cell indices (and other parameters) are important in evaluation, including Hb (haemoglobin), RBC (red blood cell count), MCH (mean corpuscular haemoglobin content), MCV and some labs use RDW (red cell distribution width), which is the standard deviation of the red cell size measurements expressed either as a percentage of the mean or a coefficient of variation.

RDW can potentially discriminate between thalassaemia carriers and iron deficiency and sometimes between thalassaemia carriers and a thalassaemia disorder or other rare causes of microcytosis, as indicated by decreased MCV (see notes below). It is a measure of the degree of anisocytosis and is simpler and faster than performing red cell morphology analysis (see Supplementary Information), although not as comprehensive. RDW alone is not a diagnostic parameter for thalassaemia trait.

The RBC count is also a parameter that can potentially distinguish between iron deficiency and thalassaemia. High RBC (erythrocytosis) results from a mechanism that compensates for the chronic low MCH present in thalassaemia carriers. This compensating mechanism needs folic acid levels to be maintained and may restore the Hb level of a markedly microcytic thalassaemia carrier to near normal values, raising RBC to 6–7 (10^{12}/l) or higher, without exceeding the normal packed cell volume (PCV) level. On the other hand, RBC compensation might be less evident in case of folic acid deficiency, a vitamin with limited body reserves, which is essential for cell division and thus for erythropoiesis. In case of folic acid deficiency carriers may become more anaemic, and microcytosis may become less evident, even disappearing in cases with coexisting vitamin B12 deficiency. In addition, RBC compensation is less evident in cases when MCH is only moderately reduced.

Interpretation of CBC, should consider the following:

- Key cut-off values in adults are MCV below 79 fl and an MCH below 27 pg, below which heterozygosity for thalassaemia is indicated. However, each laboratory should establish their own cut-off ranges for these parameters, based on the ethnicity of their patient population(s) and patient age group(s).
- Evaluation of CBC in samples more than 24 h after sampling should be made with caution, as the red cells increase in size, leading to falsely raised MCV. On the other hand, the MCH may be stable for up to 5 days, depending on storage conditions (4–20 °C);
- In advanced pregnancy the RBC is not a useful parameter, due to possible haemodilution. Furthermore, iron-deficient women who are responding to iron supplementation may have increased RBC.
- The RDW may be altered in several cardiac and hepatic conditions and may have a limited discriminating potential especially in cases with combined iron deficiency.

Haemoglobin (Hb) pattern analysis
For a presumptive identification of abnormal haemoglobins at least two methods should be used. These methods include haemoglobin electrophoresis at pH 8.6 using cellulose acetate membrane, haemoglobin electrophoresis at pH 6.0 using acid agarose or citrate agar gel, isoelectric focusing (IEF), high performance liquid chromatography (HPLC) and capillary electrophoresis (CE). More details of these methods are described in the Supplementary information.

There are many recommendations related to the optimum application and interpretation of haemoglobin pattern analysis. The use of both HPLC and CE will maximize the detection of any Hb variant present in a sample and minimize false evaluation of artefacts. With automated systems, standards and controls are essential to verify that the equipment is working satisfactorily. Other important recommendations are summarized in the Supplementary Information.

Interpretation of Hb pattern analysis when common β-variants interact with α-thalassaemia
In carriers of the most common β-chain variants (Hb S, Hb D-Punjab, Hb E and Hb C) the percentage of the variant haemoglobin is directly dependent on the number of α-globin genes. In the presence of α-thalassaemia it is usually decreased, e.g., to less than ~35% for Hb S, D-Punjab and Hb C and less than ~25% for Hb E, although precise measurements may vary depending on the technology used. In the absence of iron deficiency, the percentage of Hb variant may therefore indicate the presence of co-inherited α-thalassaemia and help exclude β-thalassaemia as a cause of red cell microcytosis; it is a particularly useful observation to make in people of ancestral origins where both Hb E and α^0-thalassaemia are prevalent. However, this information is not reliable enough to definitely exclude the presence of α-thalassaemia because of the possibility of additional co-inheritance of multiple α-globin gene duplications (e.g. triplicated or quadruplicated rearrangements).

It is of note that for some stable β-chain variants that are more negatively charged than Hb A, such as Hb J, the relationship is inversed, as the number of α-globin genes decreases, so the percentage of Hb variant increases in the presence of α-thalassaemia.

Quantification of Hb A\textsubscript{2}
Measurements should be carried out on freshly drawn anti-coagulated blood. Methods include electrophoresis and elution, microchromatography, HPLC, capillary electrophoresis, Hb electrophoresis (not recommended).

It is important to note that the quantification of Hb A\textsubscript{2} using both HPLC and CE may still be compromised in the presence of common or rare β-chain variants, or δ chain variants, which split the Hb A\textsubscript{2} peak, or coexisting δ thalassaemia, which decreases the Hb A\textsubscript{2} peak. The use of internal controls are recommended as well as adherence to instructions provided by the manufacturers.

Haemoglobin variants which elute with or close to Hb A\textsubscript{2} on HPLC or capillary electrophoresis may affect Hb A\textsubscript{2} quantification.
Important points for the interpretation of results for Hb A₂ quantification include:

- Hb A₂ levels above 3.5% is the standard cut-off value, above which heterozygosity for β-thalassaemia is indicated.
- Borderline levels of 3.1–3.5% Hb A₂ (depending upon the method, the laboratory reference range and coefficient of variation) indicate further investigation required (see Tables 5, 6 and Supplementary Table 3).
- Reference intervals in normal subjects are usually between 2.0 and 3.3%, but have been observed to differ slightly depending on the method and population group.
- Rare genetic and acquired factors that may increase or reduce Hb A₂ levels are reported in Supplementary Table 3.

Quantification of Hb F
Methods reliable for the measurement of Hb F levels include alkali denaturation, HPLC and CE, with the latter two methods being more recent and much more accurate. More details on these methods are outlined in the Supplementary Information.

Important points for the interpretation of results for Hb F quantification include:

- Normal levels of Hb F are usually below 1% after the age of 2 years. Adults with Hb F > 2% should undergo further investigation.
- In carriers of typical elevated Hb A₂ β-thalassaemia or in carriers of Hb S, Hb F levels are usually within the normal range. When elevated (up to ~7–8%) this is usually due to co-inheritance of other globin gene variations. (e.g. co-inheritance of a triplicated β-globin allele with heterozygous β-thalassaemia) or specific β-globin gene cluster haplotypes (e.g. γ-globin gene promoter variations such as the Cγ-gene promoter Xmn-I polymorphism or the Arab-Indian or Senegal haplotypes in Hb S carriers) or variants of non-globin genes that affect γ-globin gene transcription.
- Elevated Hb F values, usually > 5%, are associated with δβ or γδβ-thalassaemia heterozygotes (along with normal or low Hb A₂ levels and reduced RBC indices) or hereditary persistence of fetal haemoglobin (HPFH).
- Raised Hb F levels can also be caused by bone marrow malignancies, aplastic anaemia, Fanconi anaemia, erythropoietic stress, treatment with certain cytotoxic agents (e.g. hydroxyurea) or pregnancy.
- In pregnancy Hb F may increase up to around 3%, making values in the range of 3–5% difficult to interpret. Values of Hb F above 5% during pregnancy may indicate the presence of heterocellular HPFH, and follow-up 6 months after delivery is recommended to clarify the Hb F levels.
- Hb F can be equally distributed in all cells (pancellular) or limited to a sub-population of red cells called Hb F cells (heterocellular) depending upon the underlying cause. Since Hb F cells in heterozygous β- or δβ-thalassaemia are larger than those with low amounts of Hb F, microcytosis may be masked. Alternatively an increased RDW may be observed.

Iron (Fe) status
There are several parameters that can be measured to evaluate the iron status of an individual, including Zinc protoporphyrin (ZnPp) serum ferritin and transferrin saturation measurements.

The interpretation of all three parameters should be done with some caution. Measurement of iron status in samples with hypochromic, microcytic indices but with normal Hb A₂ and F is useful to distinguish between cases of iron deficiency and those with possible α-thalassaemia trait or certain form of ‘silent’ β-thalassaemia trait, the latter of which should have normal iron status. This distinction is useful to prevent unnecessary further investigation as well as inappropriate iron therapy. However, it is important to note that iron deficiency can co-exist with the thalassaemias, which could lead to misinterpretation. If an individual is found to be iron deficient, it is recommended to repeat the haematology screen once the individual is iron replete, although this may not always be practical or feasible in a couple with an on-going pregnancy.

SECOND-LINE HAEMATOLOGICAL METHODS
There are several methods which are not necessarily first-line methods for identifying thalassaemia carriers but may be useful in supporting the diagnosis in cases which do not have a clear diagnosis with first-line methods described previously. These (Supplementary Methods) include measurement/evaluation of red cell morphology (RCM), reticulocytes and F-cells, HbH inclusions, the single tube osmotic fragility test (OF), globin chain synthesis, globin chain separation, solubility or sickling tests for Hb S, DCIP (2.6 dichlorophenolindophenol) test, Heinz body formation and the measurement of an oxygen dissociation curve. Mass spectrometry is also described as a second-line method for the characterization of Hb variants identified by first-line methods such as HPLC. However, it potentially has a role as a first-line test, where it may be used more widely for carrier screening. All these second-line tests are discussed in the Supplementary Information.

REPORTING HAEMATOLOGY RESULTS
Haematology results should be given following complete evaluation of all relevant haematological parameters. Reporting should be done in a format complying with local legislation, regulations and acceptable practice. The report should be written clearly to avoid misinterpretation. If possible it should be accompanied by relevant information materials, currently most important for health practitioners in non-endemic countries who may not have experience with the haemoglobinopathies. The report should recommend referral of carrier couples or affected children to a relevant healthcare professional and encourage that testing be offered to additional family members.

Recommended formats for reporting haematology results can be found in the UK NHS Sickle Cell and Thalassaemia: Handbook for Laboratories.
hybridization (aCGH). All are recommended for in the context of best practice, each method having its own advantages and limitations (Tables 6a and 6b). The particular methods chosen by a laboratory for the diagnosis of the globin gene nucleotide variants or deletions depends not only on the technical expertise available but also on the type and variety of the variants likely to be encountered in the individuals (population groups) being tested. All molecular genetic methods should be validated before clinical use.

It is paramount that all DNA diagnostic laboratories take appropriate measures to preclude false-positive and especially false-negative results. The correct characterization of genotypes in carriers is extremely important to support appropriate genetic counselling and
essential prior to performing prenatal diagnosis if this is the choice of the woman (or carrier couple).

Recommendations
For genotype characterization in carriers, optimal DNA analysis results can be achieved by adhering to the following:

- Before DNA analysis, to evaluate haematology so as to direct the most appropriate molecular analysis for each sample.
- Post DNA analysis, to co-evaluate haematology to preclude a serious misinterpretation of results (misdagnosis).
- Evaluation of family history and haematology in some cases if relevant.
- Preferably to have available for use more than a single DNA analysis protocol for characterizing the genotype in carriers (prospective parents), in order to support cross-checking of results (see Tables 6a and 6b).
- If Sanger sequencing is the only method available for characterizing nucleotide variations then it is recommended that the target region in the gene of interest be analysed in duplicate, and in both the forward and reverse directions. Ideally the Sanger sequencing reaction should be performed on templates amplified by two alternative sets of primers, or, if this is not feasible, at least on duplicate templates independently amplified from the original DNA sample. In the latter case, false-negative results should be prevented by careful co-evaluation of haematology results (see above).
- If a GAP-PCR analysis produces a negative result in individuals with haematology otherwise indicating a carrier status involving a likely deletion-variant (for example z-thalassaemia), then it is recommended that either MLPA or aCGH be used to further investigate the DNA sample.

DNA extraction methods for the diagnosis of haemoglobinopathies are the same as for the molecular analysis of any other genetic disorder. General guidelines for DNA extraction methods can be found within the Best Practice Guidelines for Laboratory Internal Quality Control (http://www.cmgs.org/).

Diagnostic strategy for DNA analysis
The most common haemoglobinopathies (which have autosomal recessive inheritance) are traditionally population-specific, with each population having a unique combination of abnormal haemoglobins and/or thalassaemia disorders. The spectrum of variants and their frequencies have been published for most populations, and usually consist of a limited number of common variants and a slightly larger number of rare variants.12,13 Therefore knowledge of the ethnic origin and family history (including consanguinity) of a patient may support the diagnostic strategy, to expedite identification of the underlying defects in most cases. With the advent of global migration, however, this is becoming less practical and useful.7,12

z-Thalassaemia: Gap-PCR (amplification across the breakpoints of a deletion) provides a quick diagnostic test for most of the known z-thalassaemia and z-thalassaemia deletion variants. For prenatal diagnosis Gap-PCR requires careful application and interpretation, since it may be susceptible to false negative results caused by allele drop out (ADO). The first gap-PCR assays were subject to technical failure through ADO, but the more recently published primers and conditions support more robust assays.31,32

Many of the common z-thalassaemia deletions can be diagnosed by gap-PCR: the –SEA allele, found in Southeast Asian individuals; the –MED1 and -(z)20.5 alleles found in Mediterranean individuals; the –FIL allele, found in Filipino individuals and finally the –THAI allele, found in Thai individuals. The two most common z-thalassaemia deletions (the –x3.7 and –x4.2 alleles) can be detected by gap-PCR. The –x3.7 deletion is found most commonly in African, Mediterranean, Asian and Southeast Asian populations, while the –x4.2 deletion is found most commonly in Southeast Asia and the Pacific populations. However it is good practice to screen for both deletions in all individuals suspected of being an z-thalassaemia carrier. (For HGVS nomenclature of variants, see the HbVar database: http://globin.bx.psu.edu/hbvar/menu.html and Table 1 in the Supplementary Information.)

Southern blotting using g-gene and z-gene probes was traditionally used to diagnose all other z- and z-thalassaemia deletion variants as well as g-gene triplications and quadruplications. However, it can only detect larger segmental duplications or deletions for which probes are available. For these rare copy number variations (deletions and duplications) involving larger chromosomal regions multiplex ligation-dependent probe amplification (MLPA) represents a robust method, which has largely replaced Southern blotting in many laboratories.

MLPA is a technology based on ligation of multiple probe-pairs hybridized across the entire locus of interest, followed by amplification, facilitated through the use of universal-tag PCR primers for all ligated probe pairs, and subsequently fragment analysis. The use of universal PCR means that amplicons are generated with comparable efficiency and thus the method is semi-quantitative. In this way MLPA can detect deletions or duplications across the locus analysed and represents a valuable alternative or supplementary method to gap-PCR when investigating known and unknown deletions and duplications underlying z, g- or g-thalassaemia.33–36 Commercially available MLPA kits for the z and the g-globin gene clusters are available45 (www.lgtc.nl).

z-thalassaemia may also be caused by nucleotide variants in either of the duplicated z-globin genes. All non-deletion alleles can be detected by PCR using a technique of selective amplification of each z-globin gene, followed by DNA sequence analysis.37,38 Alternatively if the common non-deletion variants in the local population are known, the use of variant-specific tests is practical and can be recommended (Table 6a).

g-Thalassaemia: Traditionally, a limited number of g-thalassaemia variants were prevalent in most of the populations at risk for severe thalassaemia syndromes and this permitted the most appropriate targeted methods to be selected according to the ethnic origin. The most commonly used procedures for known variants included the reverse dot blot analysis with allele specific oligonucleotide probes,39 primer specific amplification (ARMS),40 and RE-PCR for a limited number of variants.41 Currently, with the trend of global migration, variant spectrums within geographical regions have become much broader. Thus the more generic method of direct Sanger sequencing (automated) has become more relevant for detecting and characterizing point variants. Real-time PCR42 and pyrosequencing43 are robust alternative methods in laboratories with the necessary instrumentation.

Gene scanning methods such as DGGE44 or HRMA45 are also useful for locating (or excluding) possible variants within the g-globin gene, HBB. They are advantageous as they provide a means to reduce the use (effort and cost) of targeted assays or sequencing, and have proved reliable and relatively inexpensive to run. However, since they do not definitively characterize nucleotide changes, when they are used within a diagnostic setting, it is imperative to subsequently
characterize any nucleotide variation indicated, using either targeted direct variant assays or automatic sequencing.

Small deletions can be detected by polyacrylamide gel electrophoresis of an amplified β-globin gene product. Some of the known larger deletions that remove the β-globin gene may be identified by gap-PCR (including Hb Lepore, some δβ-thalassaemia and HPFH deletions) or more recently by MLPA using one of the commercially available kits.

Common Hb variants: The clinically important variants, Hb S, Hb C, Hb E, Hb D-Punjab and Hb O-Arab, can be diagnosed by dot blot hybridization, the ARMS technique or direct sequencing. All except Hb C can also be diagnosed by RE-PCR. For the many other haemoglobin variants, positive identification at the DNA level is achieved by selective globin gene amplification and DNA sequence analysis.

Reporting molecular genetic (DNA) analysis results

It is strongly recommended that molecular genetic analysis for all haemoglobinopathy cases be reported in relationship to the haematology screening results, and confirm that the genotype and phenotype are consistent. If the haematology screening results are unavailable to the DNA lab then the molecular haemoglobinopathy report should recommend that the referring physician/clinician co-evaluate the molecular result with the patients' haematology and (if relevant) clinical phenotype.

Reporting should be done in a format which conforms to local legislation, regulations and acceptable practice. The HGVS nomenclature should be used to avoid ambiguity between laboratories but whenever possible the traditional variant description should also be given. Most of these are available on the HbVar Globin Gene Server: http://globin.bx.psu.edu/hbvar/menu.html.

There are several guidelines available for reporting results including those from the Swiss society of Medical Genetics (http://www.smg.ch/user_files/images/SGMG_Reporting_Guidelines), the Clinical Molecular Genetics Society (CMGS) (http://www.cmgs.org/BPGs/Reporting%20guidelines%20Sept%202011%20APPROVED.pdf), the OECD (http://www.oecd.org/science/biotechnologypolicies/38839788) and the UK NHS Sickle Cell and Thalassaemia screening programme.

FETAL DNA ANALYSIS

It is best practice for all couples undergoing prenatal diagnosis to be counselled by a qualified health professional well versed in the molecular diversity of the haemoglobinopathies. No woman should undergo prenatal diagnosis unless she has been counselled by a qualified health professional, and preferably been provided with appropriate information materials. A good selection of these are available on the web-pages www.chime.ucl.ac.uk/APoG1, http://www.enerca.org, and the NHS web-page http://sct.screening.nhs.uk/2.3 Irrespective of the couples’ previous experience, counselling should be offered for each pregnancy found to be at risk.

Prenatal diagnosis laboratories may or may not be associated with a cytogenetics laboratory. Either way it is highly recommended that women are also evaluated for the risk of transmitting other conditions, and should be offered any relevant tests. One common example is karyotype analysis for women with a high-risk of carrying a trisomy 21 pregnancy. The cytogenetics laboratory may also support the option of fetal sample backup cultures.

Due to the number of individuals involved in the care of a patient, many of whom may be at different geographical locations, good communication between all health professionals involved is essential.
diagnosis for maternal contamination. The prenatal diagnosis result based on an amniocentesis is available later in pregnancy compared to CVS, as amniocentesis is not usually performed earlier than the 15th week.

**Fetal blood sampling.** With fetal blood sampling, 1–2 ml of fetal blood is obtained, which can be used for molecular analysis, globin chain synthesis studies or HPLC. Fetal blood sampling may be more useful in women at-risk of thalassaemia hydrops fetalis when ultrasound examination shows hydropic features in the fetus. In these cases a quick diagnosis, available in a few minutes, may be obtained on the fetal blood using haematological techniques such as HPLC, as HB F will be absent if the fetus is affected. For haemoglobinopathies globin chain synthesis in fetal blood is no longer used by most centres as it is technically more demanding than current DNA analysis methods. In addition, fetal blood sampling is associated with a higher rate of miscarriage and results are available much later in pregnancy (after 18–20 weeks).

**Molecular analysis**

The laboratory carrying out the molecular analysis should choose the technique(s) best suited to their laboratory infrastructure, expertise and target population. The techniques, along with relative summary of advantages and limitations, are listed in Tables 6a and 6b.

Diagnostic errors may be introduced by either technical pitfalls, for example partial digestion by restriction enzymes, or inherent properties of the DNA sample such as rare nucleotide variations that may prevent annealing of the PCR primers or probes used in the protocol/method, leading to ADO. All logical steps should be taken to monitor, and thus preclude, such events. If identical methods are used to identify the variants in the parents and subsequently to analyse the fetal DNA, then any pitfalls caused by rare nucleotide variations will be previously identified and can be addressed by adapting the diagnostic strategy accordingly.

**Recommendations:**

- Before performing a prenatal diagnosis, the genotypes in the prospective parents should be accurately characterized and confirmed (if the women’s partner not available for testing, see above).
- Simultaneously with the fetal DNA, always analyse parental DNA sample(s) and appropriate control DNA within the test batch, preferably all as duplicates. Always include PCR blanks and, optionally, sample blanks (e.g., some labs include a DNA extraction control sample using reagents from the extraction procedure).
- Perform repeat variant test(s) on the fetal DNA, along with relevant controls, possibly with different DNA concentrations.
- Use a limited number of amplification cycles to minimize co-amplification of any maternal DNA. This is especially important when using ARMS PCR for prenatal diagnosis, as there may be a risk of preferential amplification of maternal alleles.
- For optimal accuracy of a prenatal result, one approach is to base all prenatal diagnosis results on two independent diagnostic methods to identify/investigate each parental risk allele (variant).
- There are several commercially available STR kits, such as the Amp FISTR Identifier kit (ABI), which analyses 16 STR markers. When the fetal globin genotype is the same as that of the mother, and there are no informative markers to indicate the presence or absence of maternal contamination, the fetal diagnosis report should state these findings and indicate a greater risk of error in the fetal result.

**Maternal contamination**

It is recommended that a maternal cell contamination test be performed on all prenatal specimens in order to rule out significant contamination of fetal DNA with maternal DNA. It is important to consider that all CVS and AF samples (with or without culture) may have maternal contamination. Although chorionic villus samples should be carefully dissected to remove maternal tissue, it is still important to check that maternal contamination is not present. Monitoring for maternal contamination is achieved by the analysis of polymorphic DNA sites in the fetus versus parental DNA samples.

**Recommendations:**

- The possibility of maternal DNA contamination should be investigated (and preferably excluded) in every case. It is recommended to use a panel of short tandem repeat polymorphisms (STRs). There are several commercially available STR kits, such as the Amp FISTR Identifier kit (ABI), which analyses 16 STR markers. When the fetal globin genotype is the same as that of the mother, and there are no informative markers to indicate the presence or absence of maternal contamination, the fetal diagnosis report should state these findings and indicate a greater risk of error in the fetal result.
- In dichorionic diamniotic twins (DCDA) where it is important to obtain an accurate diagnosis for each twin, STR analysis should be used to confirm there has been no twin-to-twin sample mixing, during fetal sampling. This is particularly important if the sample was obtained by CVS. In such cases, reporting the fetal sex may also be beneficial to obstetricians in the event that they have to carry out a selective termination.
- If the paternal DNA sample is analysed in addition to the fetal and maternal DNA samples, then these tests may also identify non-paternity. Such incidental findings should be handled according to local practice. In laboratories which do not routinely analyse paternal samples when performing prenatal diagnosis, paternity is assumed to be true and the prenatal report should state that the accuracy of the diagnosis is based on declared relationships.

**Patient consent and reports**

According to local practices and legislation, there should be a consent form signed by the patient and counsellor accompanying the diagnostic samples, consenting to DNA testing, DNA storage and, if appropriate, the use of the remaining DNA for standardizing and developing new tests.

The fetal DNA report should detail the types of DNA analysis performed and clearly state the risk of misdiagnosis based on the reported technical errors of the protocols utilized.

**Prenatal diagnosis follow-up**

If there are no restrictions by local conditions and practices, it is desirable to confirm the fetal DNA diagnosis at birth through a request for a cord blood sample (the request may be sent out with the fetal diagnosis report). Haematological, haemoglobin and DNA analysis are also requested by some centres. It is important that centres are trained in the collection of pure cord blood samples, otherwise there is a risk the cord blood is contaminated with maternal blood.

Where neonatal screening programmes for sickle cell and haemoglobinopathies are available then networking to obtain neonatal
screening results for babies that have undergone prenatal diagnosis, will negate the need for requesting a cord blood sample.

When affected pregnancies are terminated, ideally fetal material should be requested to confirm the prenatal diagnosis result. However, these samples are rarely received by the requesting laboratory.

Audit
National registers should exist to audit services for prenatal diagnosis. In the UK the three diagnostic laboratories enter data for each diagnosis onto a shared register and aggregated data can be used for national audit of antenatal carrier screening and utilization of prenatal diagnosis by risk, ethnic group and region. It can also be used to report on the accuracy of prenatal diagnosis.50–52 Audit should be an on-going activity that aims to identify any weaknesses in the prenatal diagnosis services, directing ways for improvement.

DEDICATION
Following the very sad news about the premature death of Professor Renzo Galanello in May 2013, the authors of these Best Practice Guidelines have decided unanimously to dedicate them to him, as he made substantial contributions to all sections. Renzo was a pioneer in the field of thalassaemia research, diagnosis and prevention, and also in the treatment and management of patients with haemoglobinopathies. The global thalassaemia community has lost a great scientist, researcher, compassionate clinician and colleague.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
The Best Practice Meeting for Haemoglobinopathies, which took place in Leiden, 5–6 September 2012, was jointly organized and financed by The European Molecular Genetics Quality Network (www.emqn.org) and EuroGentest (www.eurogentest.org; EU Contract no. FP6-512148). We thank Simon Patton and Outil Kamarain for their support. All expert authors were involved in drafting the paper, revising it critically and approval of the final version. All attendees of the Best Practice meeting were involved in critically revising the draft and approval of the final version. We would also like to thank the attendees: Debra Taylor, Mater Health Services, South Brisbane, Australia. E-mail: debra.taylor@mater.org.au. Pierre Hopmeier, Central Laboratory & Karl Landsteiner Institute, KA Rudolfstiftung, 1030 Vienna, Austria. E-mail: pierre.hopmeier@extern.wienka.at. Pascale Cochoy, Laboratoire de Genétique Moléculaire, Hospital Erasme, 808, Route de Lennik, 1070 Brussels, Belgium. E-mail: pascale.cochoy@erasme.ulb.ac.be. Cecile Libioulle, Human Genetic Centre, CHU of Liege, University of Liege, Liege, Belgium. E-mail: C.Libioulle@chu.ulg.ac.be. Thessalia Papasavva, Molecular Genetics Thalassaemia Department, The Cyprus Institute of Technology and Genetics, Nicosia, Cyprus. E-mail: thesalia@cing.ac.cy. Hanno Roomere, Estonia. Asper Biotech Ltd., 17a Vakasli St., 30410 Tartu, Estonia. E-mail: hanno.roomere@asperbio.com. Serge Pissard, APHP and UPEC University, Genetics Lab, GHU Henri Mondor, 51 av du Marechal de Lattre de Tassigny, 94010 CRETEIL, France. E-mail: Serge.pissard@inserm.fr. Raina Yamamoto, MVZ Dortmund Dr. Eberhard & Partner, Molecular Genetics, Braufurstr. 4, 44137 Dortmund, Germany. E-mail: yamamoto@labmed.de, Frank Austrup LADR-MVZ Recklinghausen, Department of. Human Genetics, Berghäuser Str. 295, 45659 Recklinghausen, Germany. E-mail: austrup@labor-re.de, Vince Jenkins, National Centre for Hereditary Coagulation Disorders, St James Hospital, Dublin, Ireland. E-mail: Vjenkins@STJAMES.IE. Anna Ravani, Laboratorio Genetica Molecolare, U.O. Genetica Medica, Azienda Ospedaliero Universitaria S.Anna di Ferrara, Italy. E-mail: rvn@unif.it. Michela Grosso, University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Via Sergio Pansini 5, 80131 Naples, Italy. E-mail: michela.grosso@unina.it. Cristina Curcio, Molecular Genetics Laboratory. Fondazione IRCCS Ca’ Granda, Osp. Maggiore Policlinico, Via F. Sforza, 28, 20122 Milan, Italy. E-mail: cristina6709@libero.it. Ma Celeste Abad, Mol. Cytogenetics Laboratory, Research And Biotechnology Division, St. Luke’s Medical Center, Quezon City Philippines. Email: ma.celeste.soriano@gmail.com. Janet Pereira, Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. E-mail: janet.pereira@chc.min-saude.pt. Celeste Bento, Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. E-mail: celeste.bento@chc.min-saude.pt. João Gonçalves, Unidade de Genetica Molecular, Departamento de Genetica Humana, Instituto Nacional de Saude Dr Ricardo Jorge, Av. Padre Cruz, Lisbon, Portugal. E-mail: joao.goncalves@insa.min-saude.pt. Ramin Badii, Molecular Genetics Laboratory; Hamad Medical Corporation, Doha, Qatar. E-mail: rbadii@hm.org.qa. Yuen-Ming Tan, National Thalassaemia Registry, KK Women’s and Children’s Hospital, 100, Bukit Timah Road, 229999 Singapore. E-mail: Tan.Yuen.Ming@kkh.com.sg. Dina Z. Markalanda, Human Genetics Unit, Faculty of Medicine, University of Colombo, Sri Lanka. Email: Dina.g@yahoo.com. Camilla Vallon-Andre, Section of Clinical Chemistry, Department of Laboratory Medicine, Skane University Hospital, Malmö, Sweden. E-mail: c.vallon-andre@med.lu.se. Elisabeth Seller, Institute for Medical &Molecular Diagnostics Ltd., Falkenstrasse 14, 8024 Zürich, Switzerland. E-mail: seller@mldlab.ch. Oliver Speer, Division of Hematology and Children’s Research Center, University Children’s Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. E-mail: Oliver.Speer@kispi.uzh.ch. Dr Barnaby Clark, Red Cell Centre, King’s College Hospital, Denmark Hill, London, UK. E-mail: barnaby.clark@knh.net. These Best Practice Guidelines are dedicated to the memory of Renzo Galanello.

1 Ryan K, Bain BJ, Worthington D et al: Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 2010; 149: 35–49.
2 Recommendations for preconceptional and prenatal screening, prenatal diagnosis and genetic counselling of haemoglobinopathies. http://www.enerca.org 2013.
3 UK NHS Sickle Cell and thalassemia handbook for laboratories. http://sct.screening. nhs.uk/standardsandguidelines 2013.
4 Traeger-Synodinos J, Harteveld CL: Advances in technologies for screening and diagnosis of haemoglobinopathies. Biomed Mark 2014; 8: 119–131.
5 International Organization for Standardization. http://www.iso.org/iso/home.htm 2013.
6 Berwouts S, Morris MA, Dequeker E: Approaches to quality management and accreditation in a genetic testing laboratory. Eur J Hum Genet 2010; 18(Suppl 1): S1–S19.
7 Williams TN, Weatherall DJ: World distribution, population genetics, and health burden of the haemoglobinopathies. Cold Spring Harb Perspect Med 2012; 4, a011692.
8 Steinberg MH, Forget BG, Higgs DR, Nagel RL: Disorders of hemoglobin, 2nd edn. Genetics, Pathophysiology and Clinical Management 2009.
9 Traeger-Synodinos J, Veteto C, Kanavakis E: Prenatal, noninvasive and preimplantation genetic diagnosis of inherited disorders: hemoglobinopathies. Expert Rev Mol Diagn 2011; 11: 299–312.
10 Vichinsky E: Complexities of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Ann N Y Acad Sci 2010; 1202: 180–187.
11 Gardine B, van BS, Kaimakis P et al: HbVar database of human hemoglobin variants and thalassemia mutations. 2007 update. Hum Mutat 2007; 28: 206.
12 Modell B, Darlison M, Birgens H et al: Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest 2007; 67: 39–69.
13 Old J, Angastiniotis M, Eleftheriou A et al: Prevention of Thalassemias and Other Haemoglobin Disorders, Principles. 2nd edn, 2013; Nicosia, Cyprus: Thalassaemia International Federation.
14 Dacie JV, Lewis ME: Practical Haematology, 11th edn, 2011; Elsevier.
15 Buch AC, Karwe PP, Panicker NK, Singru SA, Gupta SC: Role of red cell distribution width in classifying microcytic hypochromic anaemia. J Indian Med Assoc 2011; 109: 297–299.
16 Stephens AD, Angastiniotis M, Baysal E: ICSH recommendations for the measurement of haemoglobin A2. Int J Lab Hematol 2012; 34: 1–13.
17 Stephens AD, Angastiniotis M, Bayesal E et al: ICSH recommendations for the measurement of haemoglobin F. Int J Lab Hematol 2012; 34: 14–20.
18 van Delft P, Lenties E, Bakker-Vermeij M et al: Evaluating five dedicated automatic devices for haemoglobinopathy diagnostics in multi-ethnic populations. Int J Lab Hematol 2009; 31: 484–495.
19 Bunn HF, McDonald MJ: Electrostatic interactions in the assembly of haemoglobin. Nature 1983; 306: 498–500.
20 Giordano PC: Editorial: measurement of HbA2. Int J Lab Hematol 2012; 34: 335.
21 Paleari R, Gulbis B, Cotton F, Mosca A: Interlaboratory comparison of current high-performance methods for HbA2. Int J Lab Hematol 2012; 34: 362–368.
22 Philipson M, Gallivan MV, Arkestenin SG, Harteveld CL, Giordano PC: Occurrence of common and rare delta-globin gene defects in two multiethnic populations: thirteen
new mutations and the significance of delta-globin gene defects in beta-thalassemia per se. [Int J Lab Hematol] 2011; 33: 85–91.

23 Pereseau L, Satta S, Moi P et al: KLF1 gene mutations cause borderline HbA2(1). [Blood] 2011; 118: 4454–4458.

24 Pembrey ME, McBride P, Weatherall DJ: Reliable routine estimation of small amounts of fetal haemoglobin by alkali denaturation. [J Clin Pathol] 1972; 25: 738–740.

25 World Health Organization/Centers for Disease Control and Prevention: Assessing the Iron Status of Populations: Including Literature Reviews: Report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level, 6–8 April 2004; 2nd edn. Geneva, Switzerland: World Health Organization, 2007.

26 Leers MP, Pelikan HM, Salemans TH, Giordano PC, Schamhourd V: Discriminating fetomaternal hemorrhage from maternal HbF-containing erythrocytes by dual-parameter flow cytometry. [Eur J Obstet Gynecol Reprod Biol] 2007; 134: 127–129.

27 Singh SP, Gupta SC: Effectiveness of red cell osmotic fragility test with varying degrees of saline concentration in detecting beta-thalassaemia trait. [Singapore Med J] 2008; 49: 823–826.

28 Giordano PC, van Delft P, Batelaan D, Harteveld CL, Bernini LF: Haemoglobinopathy analyses in the Netherlands: a report of an in vitro globin chain biosynthesis survey using a rapid, modified method. [Clin Lab Haematol] 1999; 21: 247–256.

29 Chapple L, Harris A, Phelan L, Bain BJ: Reassessment of a simple chemical method for quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. [Hum Mutat] 2004; 20:5 7–67.

30 White SJ, Vink GR, Kriek M: Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. [Proc Natl Acad Sci USA] 2002; 99: 12515–263.

31 Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB: Discriminating alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. [Br J Haematol] 2000; 108: 295–299.

32 Chong SS, Boehn CD, Higgs DR, Cutting GR: Single-tube multiplex-PCR screen for alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex ligation-dependent probe amplification. [Hum Genet] 2001; 108: 691–704.

33 Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. [Nucleic Acids Res] 2002; 30: e57.

34 White SJ, Vink GR, Kriek M et al: Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. [Hum Mutat] 2004; 24: 86–92.

35 Harteveld CL, Voskamp A, Phylipse M et al: Nine unknown rearrangements in 16p13.3 and 11p15.4 causing alpha- and beta-thalassaemia characterised by high resolution multiplex ligation-dependent probe amplification. [J Med Genet] 2005; 42: 922–931.

36 Harteveld CL, Refaii C, Cassinerio E, Cappellini MD, Giordano PC: Segmental duplications involving the alpha-globin gene cluster are causing beta-thalassaemia intermedia phenotypes in beta-thalassaemia heterozygous patients. [Blood Cells Mol Dis] 2008; 40: 312–316.

37 Harteveld KL, Heister AJ, Giordano PC, Losekoot M, Bernini LF: Rapid detection of point mutations and polymorphisms of the alpha-globin genes by DGGE and SSCP. [Hum Mutat] 1996; 7: 114–122.

38 Ko TM, Tseng LH, Hsieh FJ, Lee TY: Prenatal diagnosis of Hb H disease due to compound heterozygosity for South-east Asian deletion and Hb constant spring by polymerase chain reaction. [Prenat Diagn] 1993; 13: 143–146.

39 Saiki RK, Walsh PS, Levenson CH, Erlich HA: Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. [Proc Natl Acad Sci USA] 1989; 86: 6230–6234.